© 2004 by BMJ Publishing Group Ltd & European League Against Rheumatism
REPORT
Genetics
Pharmacogenetics in the rheumatic diseases
Correspondence to:
Correspondence to:
Professor B N Cronstein
New York University School of Medicine, 550 First Ave., New York, NY 10016; cronsb01@med.nyu.edu
Abbreviations: AICAR, aminoimidazolecarboxamidoribonucleotide; MTHFR, methylene tetrahydrofolate reductase; RA, rheumatoid arthritis; TPMT, thiopurine methyl transferase
Keywords: azathioprine; folic acid; methotrexate
| The first 150 words of the full text of this article appear below. |
One of the promises of the human genome project is individualised pharmacological therapy. An individuals genetic type would be determined, and the resulting diseases which the person was susceptible to would be determined. In addition, the drugs to which an individual would respond well would be enumerated, and the drugs which were more likely to be toxic could be established. At present we are just beginning to determine those associations which would help us tailor an individuals pharmacological therapy so as to maximise efficacy and minimise toxicity. In this report we review the considerations involved in determining the pharmacogenetic profile of any given drug and to review the current level of understanding of the association between genetic polymorphisms and drug toxicity/efficacy in rheumatology.
Establishing an association between genetic types and toxicity is perhaps an easier task to accomplish than understanding the association between a given genetic type and drug
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
